Navigation Links
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
Date:5/4/2011

b>Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the potential therapeutic indication and use, FDA approval and commercialization of lorcaserin; the Eisai collaboration and potential activities thereunder; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain; the risk that data and other information related to Arena's clinical trials and other studies, including for lorcaserin, may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's resubmission of the lorcaserin NDA may not be submitted when anticipated, if at all; the FDA may request other information prior to or after Arena resubmits the lorcaserin NDA or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner Arena or others expect or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
2. Arena Pharmaceuticals Expands GPR119 Patent Portfolio for Type 2 Diabetes
3. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11
4. Arena Pharmaceuticals Announces Upcoming Departure of Chief Financial Officer
5. Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
6. Arena and Eisai Complete End-of-Review Meeting with FDA for Lorcaserin New Drug Application
7. Arena Pharmaceuticals to Host Conference Call and Webcast to Provide Update Following Lorcaserin End-of-Review Meeting With FDA
8. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
9. Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
10. Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
11. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Immune Therapeutics, Inc. today announced the ... the compounding, packaging and distributing of its naltrexone tablets.  The ... United States . KRS Global is ... tablets in various strengths for individual patients in response to ...
(Date:1/23/2015)... 2015  iMD Companies, Inc. (ICBU) has repositioned itself as a ... grab a foothold in the hydroponic, hemp and medical marijuana ... presence in the sector, and recently partnering with the Chippewa ... and medical marijuana, iMD is committing to bring its vision ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... SAN DIEGO, Oct. 28 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... 30, 2009. For the third quarter of 2009, the Company reported ... with a net loss of $17.7 million, or $0.46 per share, ... September 30, 2009, the Company reported a net loss of $43.1 ...
... BATESVILLE, Ind., Oct. 28 Hill-Rom Holdings, Inc. (NYSE: ... and 2010 financial guidance on Wednesday, November 11, 2009. ... morning on Thursday, November 12, 2009 at 7:30 a.m. EST. ... Quarter Earnings and 2010 Financial Guidance release will be issued ...
Cached Medicine Technology:Neurocrine Biosciences Reports Third Quarter 2009 Results 2Neurocrine Biosciences Reports Third Quarter 2009 Results 3Neurocrine Biosciences Reports Third Quarter 2009 Results 4Neurocrine Biosciences Reports Third Quarter 2009 Results 5Neurocrine Biosciences Reports Third Quarter 2009 Results 6Neurocrine Biosciences Reports Third Quarter 2009 Results 7Neurocrine Biosciences Reports Third Quarter 2009 Results 8Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Fourth Quarter Earnings and 2010 Financial Guidance Webcast 2
(Date:1/22/2015)... January 22, 2015 Gabe’s Chemo Duck Program is ... the first app ever created for kids with cancer. The Chemo ... and devices, is filled with enjoyable games to help children of ... The free app helps to keep kids entertained, educated and at ...
(Date:1/22/2015)... is a famous wedding dress company offering many trendy designs. ... Facebook, Twitter, and Pinterest. The fans will have an opportunity ... every week. , Moreover, the company has extended its 2015 ... homepage for more information. , Angelweddingdress is a ...
(Date:1/22/2015)... 22, 2015 Juvent Sports ( http://www.juventsports.com ... 2015 PGA Merchandise Show to bestow a Juvent Sports ... amateur golfer, Arlene McKitrick. The award commemorated and congratulated ... tournament win. She won her first amateur tournament in ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... Blood ... Pressure Up to 30 Points, ... that the United States Food and Drug Administration (FDA),has approved ... known as high blood pressure. AZOR is a,convenient, once daily, ...
... to be higher than for whites, study finds , , THURSDAY, ... diabetes who take drugs to control their disease are less ... a new study finds. , Two factors appear to account ... to medications and emotional responses to having diabetes, according to ...
... QMED ) today announced it expects to report for ... of approximately $10.8 million and,$26.6 million and a net ... cash position as of August 31st, 2007 is,approximately $6.4 ... and CEO, said, "During the months of July and,August, ...
... the Largest and the ... Becomes McLaren,s Newest Subsidiary in Southeast ... Michigan, PONTIAC, Mich., Sept. ... care system in Michigan,McLaren Health Care is pleased to announce the addition of POH ...
... PARIS, Sept. 27 KARL LAGERFELD SAS announced ... to create KARL,LAGERFELD men,s and women,s eyewear starting ... one of the most prominent eyewear companies,the exclusive ... sun and ophthalmic collections for the KARL LAGERFELD ...
... WASHINGTON, Sept. 27 - 100 Black Men of,America, Inc. ... that,will work to increase local outreach to diverse communities ... to enhance,delivery of services to diverse communities during times ... the agreement the Red Cross will provide disaster training ...
Cached Medicine News:Health News:AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure 2Health News:AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure 3Health News:AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure 4Health News:AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure 5Health News:AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure 6Health News:Older Blacks, Latinos Struggle With Diabetes Control 2Health News:Older Blacks, Latinos Struggle With Diabetes Control 3Health News:QMed, Inc. Comments on Estimated 3rd Quarter Results & Medical Expense Ratio; Sets 2008 Revenue Guidance for Medicare SNPs at $88-95 Million 2Health News:QMed, Inc. Comments on Estimated 3rd Quarter Results & Medical Expense Ratio; Sets 2008 Revenue Guidance for Medicare SNPs at $88-95 Million 3Health News:McLaren Health Care Adds POH Medical Center to System 2Health News:KARL LAGERFELD SAS Signs Global Eyewear License Agreement With Marchon Eyewear, Inc. 2Health News:100 Black Men of America, Inc. and American Red Cross Sign National Agreement to Increase Diverse Outreach Nationwide 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: